FB2026_02 , released June 18, 2026
Reference Report
Open Close
Reference
Citation
Millet-Boureima, C., Ennis, C.C., Jamison, J., McSweeney, S., Park, A., Gamberi, C. (2021). Empowering Melatonin Therapeutics with Drosophila Models.  Diseases 9(4): 67.
FlyBase ID
FBrf0251634
Publication Type
Review
Abstract
Melatonin functions as a central regulator of cell and organismal function as well as a neurohormone involved in several processes, e.g., the regulation of the circadian rhythm, sleep, aging, oxidative response, and more. As such, it holds immense pharmacological potential. Receptor-mediated melatonin function mainly occurs through MT1 and MT2, conserved amongst mammals. Other melatonin-binding proteins exist. Non-receptor-mediated activities involve regulating the mitochondrial function and antioxidant cascade, which are frequently affected by normal aging as well as disease. Several pathologies display diseased or dysfunctional mitochondria, suggesting melatonin may be used therapeutically. Drosophila models have extensively been employed to study disease pathogenesis and discover new drugs. Here, we review the multiple functions of melatonin through the lens of functional conservation and model organism research to empower potential melatonin therapeutics to treat neurodegenerative and renal diseases.
PubMed ID
PubMed Central ID
PMC8544433 (PMC) (EuropePMC)
Associated Information
Comments
Associated Files
Other Information
Secondary IDs
    Language of Publication
    English
    Additional Languages of Abstract
    Parent Publication
    Publication Type
    Journal
    Abbreviation
    Diseases
    Title
    Diseases
    ISBN/ISSN
    2079-9721
    Data From Reference